Skip to main content

Haemolysis during sample preparation alters microRNA content of plasma.

Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, Reid G

Publication: PLoS One (2011) • Vol 6 • Page e24145PMID: 21909417View on PubMed

Purpose

The purpose of this paper was to determine if hemolysis affects microRNA (miRNA, miR) levels in plasma and to determine which blood components express miR-16 and miR-451.

Conclusion

In non-hemolyzed plasma, levels of miR-16 were the highest and least variable among patients, followed by miR-451, miR-24 and miR-15b. Hemolyzed plasma had up to 2-8-fold higher levels of miR-451, miR-16, and miR-92a (a heart disease biomarker) than non-hemolyzed specimens from the same blood collection. Hemolysis was detectable by spectrophotometry with a red blood cell (RBC) concentration of as little as 0.016%. While alanine aminotrasferase (ALT) and aspartate aminotransferase (AST) only increased in specimens with visible hemolysis (RBC concentration of 0.125%), miR-451, miR-16 and miR-92a were elevated (~2-fold) with a RBC concentration of 0.031%. When a hemolysis cut-off of <0.2 absorbance units at 414 nm was applied, variability in miR-451 and miR-16 levels decreased significantly. When miRNA levels were examined in different blood components, data revealed that miR-16 and miR-451 levels were highest in RBCs, as less than 1% of the remaining levels observed in whole blood were attributable to plasma and peripheral blood mononuclear cells (PBMC).

Studies (1)

Purpose

The purpose of this study was to determine if hemolysis affects the miRNA levels in plasma, to identify a hemolysis threshold of effect, and to determine which blood components express miR-16 and miR-451. Between 1 and 3 tubes of K3EDTA blood were obtained from 9 healthy patients, 16 patients with coronary artery disease and 20 patients with malignant mesothelioma. Plasma and RBCs were stored at -80°C, but PBMC were processed immediately. RBC lysate was produced by freeze-thawing and vortexing the RBC pellet. RNA was isolated using the mirVana PARIS miRNA isolation kit and miRNA was stored at -80°C. Only 4 patients were used for the comparisons of hemolyzed and non-hemolyzed plasma from the same blood draw.

Summary of Findings

High levels of miR-16 were present in plasma, with little variation (2 cycles) among patients despite three different diagnostic categories. Levels of miR-15b and miR-24 were comparably lower than miR-16 and more variable (7 cycles) among patients. miR-451 levels and variability were intermediate to those of miR-16, and those of miR-15b and miR-24. Levels of miR-451 and miR-16 were 2-8 fold higher in hemolyzed plasma compared to non-hemolyzed specimens from the same blood collection, which corresponded to the fold increase in hemoglobin. Similarly, miR-92a (a marker of heart disease) was 2-4 fold higher in hemolyzed specimens than matched non-hemolyzed specimens from the same 4 individuals. However, levels of another heart disease biomarker, miR-155, were only elevated in 2 of the 4 hemolysed specimens, and the increase did not correspond to the fold increase in hemoglobin. Hemolysis was detectable by spectrophotometry with a RBC concentration of as low as 0.016% (v/v), while visible hemolysis was only possible with a RBC concentration of 0.125% or greater. While ALT and AST only increased in specimens with visible hemolysis (0.125%), miR-451, miR-16, and miR-92a were elevated (~2-fold) when RBC concentrations reached 0.031%. Levels of miR-155 and miR-625 were not affected by RBC concentrations of up to 0.125%. When a hemolysis cut-off of <0.2 absorbance units at 414 nm was applied, variability in miR-451 and miR-16 levels decreased significantly (p<0.008 and p<0.026, respectively), but there was no change in variability of miRNAs unaffected by hemolysis (miR-24 and miR-15b). Levels of miR-16 and miR-451 were highest in RBC, as less than 1% of the remaining levels observed in whole blood were attributable to plasma and PBMC.

  • Biospecimens

    FluidPlasma
    FluidBlood
    CellRed Blood Cells
  • Preservation Types

    FrozenNone (Fresh)
  • Diagnoses

    NeoplasticCarcinoma
    Normal
    Coronary Artery Disease
  • Platforms

    RNAReal-time qRT-PCR
    ProteinClinical chemistry/auto analyzer
    ProteinSpectrophotometry
    Cell count/volumeSpectrophotometry
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Coronary artery disease
    Healthy
    Malignant mesothelioma
    Biospecimen Aliquots and ComponentsBiospecimen components
    0% RBCs
    0.002% RBCs
    0.004% RBCs
    0.008% RBCs
    0.016% RBCs
    0.031% RBCs
    0.063% RBCs
    0.125% RBCs
    0.25% RBCs
    0.5% RBCs
    1% RBCs
    2% RBCs
    Biospecimen Aliquots and ComponentsBlood and blood products
    Peripheral blood mononuclear cells
    Plasma
    Red blood cells
    Whole blood
    Biospecimen Aliquots and ComponentsHemolysis
    Absent
    Hemolysate added
    Present
    Real-time qRT-PCR SpecificTargeted nucleic acid
    miR-155
    miR-15b
    miR-16
    miR-24
    miR-451
    miR-92a